製品番号: HY-N1067

キサントフモール

(別名: Xanthohumol)

16 Cited Publications

カスタマーレビュー

Based on 16 publication(s) in Google Scholar

Xanthohumol is one of the principal flavonoids isolated from hops, the inhibitor of diacylglycerol acetyltransferase (DGAT), COX-1 and COX-2, and shows anti-cancer and anti-angiogenic activities. Xanthohumol also has antiviral activity against bovine viral diarrhea virus (BVDV), rhinovirus, HSV-1, HSV-2 and cytomegalovirus (CMV).

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.94%
CAS 番号: 6754-58-1
分子式: C₂₁H₂₂O₅
分子量:354.40

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Xanthohumol 構造式

CAS 番号: 6754-58-1

容量

価格（税別）

在庫状況

数量

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

お問い合わせ Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability お問い合わせ Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

バルクお問い合わせ

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 臨床実験
化学情報
Publications (16)
溶剤 & 溶解度
- 体外
- 体内
プロトコル
純度とドキュメンテーション
参考文献
Help & FAQs
Bioz

生物活性

製品説明

IC₅₀ & Target^[1]^[2]^[3]^[4]^[5]

COX-1

COX-2

HSV-1

HSV-2

DGAT1

40 μM (IC₅₀)

DGAT2

40 μM (IC₅₀)

CMV

COX アイソフォーム固有の製品をすべて表示 :

Acyltransferase アイソフォーム固有の製品をすべて表示 :

HSV アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	11.9 μM Compound: Xn	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 30196062]
A549	IC₅₀	30.5 μM Compound: 8a, Xn	Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 25629304]
BGC-823	IC₅₀	7.8 μM Compound: Xanthohumol	Cytotoxicity against human BGC823 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human BGC823 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 29288946]
BV-2	IC₅₀	7.92 μM Compound: 14	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by griess assay Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by griess assay	[PMID: 29154541]
HEK293	IC₅₀	35 μM Compound: 1	Inhibition of TNF-alpha-induced NF-kappaB activation expressed in human HEK293 cells preincubated for 2 hrs before TNFalpha challenge by leuciferase reporter gene assay Inhibition of TNF-alpha-induced NF-kappaB activation expressed in human HEK293 cells preincubated for 2 hrs before TNFalpha challenge by leuciferase reporter gene assay	[PMID: 19757857]
HeLa	IC₅₀	>40 μM Compound: 8a, Xn	Inhibition of TrxR in human HeLa cells assessed as depletion of cellular thiol after 48 hrs Inhibition of TrxR in human HeLa cells assessed as depletion of cellular thiol after 48 hrs	[PMID: 25629304]
HeLa	IC₅₀	40.4 μM Compound: 8a, Xn	Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 25629304]
HeLa	IC₅₀	9.4 μM Compound: 1	Cytotoxicity against human HeLa cells by MTT assay after 72 hrs Cytotoxicity against human HeLa cells by MTT assay after 72 hrs	[PMID: 18611049]
HeLa	IC₅₀	9.4 μM Compound: 1, xanthohumol	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 18343123]
HeLa	IC₅₀	9.4 μM Compound: 7	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 20153559]
HepG2	IC₅₀	35 μM Compound: 8a, Xn	Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 25629304]
HMEC-1	IC₅₀	11.4 μM Compound: Xanthohumol	Antiangiogenic activity in SV-40T transfected human HMEC1 cells assessed as inhibition of cell proliferation after 72 hrs by crystal violet staining Antiangiogenic activity in SV-40T transfected human HMEC1 cells assessed as inhibition of cell proliferation after 72 hrs by crystal violet staining	[PMID: 23030826]
HMEC-1	IC₅₀	11.4 μM Compound: Xanthohumol	Antiproliferative activity against human HMEC1 cells after 72 hrs Antiproliferative activity against human HMEC1 cells after 72 hrs	[PMID: 25128665]
HT-29	IC₅₀	91.31 μM Compound: 1	Cytotoxicity against human HT-29 cells after 72 hrs by SRB assay Cytotoxicity against human HT-29 cells after 72 hrs by SRB assay	[PMID: 23434138]
HT-29	IC₅₀	91.31 μM Compound: 1, Xanthohumol	Antiproliferative activity against human HT-29 cells after 72 hrs by SRB assay Antiproliferative activity against human HT-29 cells after 72 hrs by SRB assay	[PMID: 23466227]
Ishikawa	IC₅₀	4.2 μM Compound: XH	Cytotoxicity against human Ishikawa cells after 96 hrs by SRB assay Cytotoxicity against human Ishikawa cells after 96 hrs by SRB assay	[PMID: 28812892]
MCF7	IC₅₀	10.95 μM Compound: 1	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 23434138]
MCF7	IC₅₀	10.95 μM Compound: 1, Xanthohumol	Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 23466227]
MCF7	IC₅₀	13.3 μM Compound: Xanthohumol	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 2 days by SRB assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 2 days by SRB assay	[PMID: 33257172]
MCF7	IC₅₀	3.47 μM Compound: Xanthohumol	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 4 days by SRB assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 4 days by SRB assay	[PMID: 33257172]
NCI-H1975	IC₅₀	13 μM Compound: Xn	Antiproliferative activity against human NCI-H1975 cells after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells after 72 hrs by MTT assay	[PMID: 30196062]
NCI-H460	IC₅₀	6.9 μM Compound: Xanthohumol	Cytotoxicity against human NCI-H460 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 29288946]
NCI-H460	IC₅₀	7.5 μM Compound: Xn	Antiproliferative activity against human NCI-H460 cells after 72 hrs by MTT assay Antiproliferative activity against human NCI-H460 cells after 72 hrs by MTT assay	[PMID: 30196062]
PC-3	IC₅₀	10.67 μM Compound: 1	Cytotoxicity against human PC3 cells after 72 hrs by SRB assay Cytotoxicity against human PC3 cells after 72 hrs by SRB assay	[PMID: 23434138]
PC-3	IC₅₀	10.67 μM Compound: 1, Xanthohumol	Antiproliferative activity against human PC3 cells after 72 hrs by SRB assay Antiproliferative activity against human PC3 cells after 72 hrs by SRB assay	[PMID: 23466227]
RAW264.7	IC₅₀	8.3 μM Compound: 1	Inhibition of LPS/IFN-gamma-induced NO production in mouse RAW264.7 cells after 16 hrs Inhibition of LPS/IFN-gamma-induced NO production in mouse RAW264.7 cells after 16 hrs	[PMID: 15679315]
SGC-7901	IC₅₀	10 μM Compound: Xanthohumol	Cytotoxicity against human SGC7901 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human SGC7901 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 29288946]
VSMC	IC₅₀	3.49 μM Compound: 1	Inhibition of PDGF-BB-induced rat VSMC proliferation preincubated for 30 mins followed by PDGF-BB addition measured after 48 hrs by resazurin assay Inhibition of PDGF-BB-induced rat VSMC proliferation preincubated for 30 mins followed by PDGF-BB addition measured after 48 hrs by resazurin assay	[PMID: 28627872]

体外実験

Xanthohumol significantly attenuates ADP-induced blood platelet aggregation, and significantly reduces the expression of fibrinogen receptor (activated form of GPIIbIIIa) on platelets' surface^[1].
Xanthohumol (5-50 nM) reduces the frequency of spontaneously occurring Ca²⁺ sparks and Ca²⁺ waves in control myocytes and in cells subjected to Ca²⁺ overload caused by: (1) exposure to low K⁺ solutions, (2) periods of high frequency electrical stimulation, (3) exposures to isoproterenol or (4) caffeine. Xanthohumol (50-100 nM) reduces the rate of relaxation of electrically- or caffeine-triggered Ca²⁺ transients, without suppressing I_Ca, but this effect is small and reversed by isoproterenol at physiological temperatures. Xanthohumol also suppresses the Ca²⁺ content of the SR, and its rate of recirculation^[2].
Treatment of endothelial cells with Xanthohumol leads to increased AMPK phosphorylation and activity. Functional studies using biochemical approaches confirm that AMPK mediates Xanthohumol anti-angiogenic activity. AMPK activation by Xanthohumol is mediated by CAMMKβ, but not LKB1. Analysis of the downstream mechanisms shows that Xanthohumol-induced AMPK activation reduces nitric oxide (NO) levels in endothelial cells by decreasing eNOS phosphorylation. Finally, AKT pathway is inactivated by Xanthohumol as part of its anti-angiogenic activity, but independently from AMPK, suggesting that these two signaling pathways proceed autonomously^[3].
Xanthohumol significantly reduces cell viability and induces apoptosis via pro-caspase-3/8 cleavage and poly(ADP ribose) polymerase (PARP) degradation. Pro-caspase-9 cleavage, Bcl2 family expression changes, mitochondrial dysfunction, and intracellular ROS generation also participate in Xanthohumol-induced glioma cell death. Xanthohumol's inhibition of the IGFBP2/AKT/Bcl2 pathway via miR-204-3p targeting plays a critical role in mediating glioma cell death^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

臨床実験

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

化学情報

CAS 番号 6754-58-1
性状 Solid
分子量 354.40
分子式 C₂₁H₂₂O₅
Color Yellow to orange
SMILES

O=C(C1=C(OC)C=C(O)C(C/C=C(C)\C)=C1O)/C=C/C2=CC=C(O)C=C2
別名

Xanthohumol
Structure Classification
- Flavonoids
- Chalcones
- Phenols
- Polyphenols
Initial Source
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (16)

All IFCell Proliferation/Viability AssayWB

Sort by:

Journal Impact Factor

Acta Pharm Sin B

Chrysin serves as a novel inhibitor of DGK α/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC). [Abstract]

2021 Jan;11(1):143-155. PMID: 33532186
J Nanobiotechnology

An oral nanocombinatorial agent exhibits pleiotropic improvement in diabetic nephropathy via modulation of the SCAP/SREBPs pathway. [Abstract]

2026 Mar 22;24(1):405. PMID: 41866523
Food Chem

Effects of sun drying combined with baking processes on the flavor quality of Chongqing Tuocha raw tea. [Abstract]

2025 Dec 30:497:146992. PMID: 41285060
Food Chem

Flavonoid-mediated metabolic underpinning quality variation in red bud-sport pear mutants. [Abstract]

2025 May 31:489:144992. PMID: 40466530
Regen Biomater

Fabrication of a 3D bioprinting model for posterior capsule opacification using GelMA and PLMA hydrogel-coated resin. [Abstract]

2024 Mar 1:11:rbae020. PMID: 38529352
Biomed Pharmacother

Developing neobavaisoflavone nanoemulsion suppresses lung cancer progression by regulating tumor microenvironment. [Abstract]

2020 Sep;129:110369. PMID: 32563983
Phytother Res

Xanthohumol Regulates Mitophagy in Osteosarcoma Cells via AMPK-ULK1-FUNDC1 Signaling Pathway. [Abstract]

2025 May;39(5):2393-2406. PMID: 40190139
Phytother Res

Xanthohumol inhibits non-small cell lung cancer via directly targeting T-lymphokine-activated killer cell-originated protein kinase. [Abstract]

2023 Jul;37(7):3057-3068. PMID: 36882184

Xanthohumol purchased from MedChemExpress. Usage Cited in: Phytother Res. 2023 Jul;37(7):3057-3068. [Abstract]

Xanthohumol (XN; 10, 15, 20 μM; 36 h) suppresses the serum-induced migratory ability of A549 cells.

Xanthohumol purchased from MedChemExpress. Usage Cited in: Phytother Res. 2023 Jul;37(7):3057-3068. [Abstract]

Xanthohumol (XN; 25 mg/kg; i.p.; single daily for 30 days) significantly suppresses the tumor growth and reduces the final tumor weight by 50.4% (Fig a-c).

Xanthohumol purchased from MedChemExpress. Usage Cited in: Phytother Res. 2023 Jul;37(7):3057-3068. [Abstract]

Xanthohumol (XN; 10, 15, 20 μM; 36 h) results in a dose-dependent inhibition of TOPK phosphorylation (Thr9), and inhibits the phosphorylation of histone H3 and Akt, in both HCC827 cells (fig c) and HCT116 cells (Fig d).
J Ethnopharmacol

Xanthohumol ameliorates OVA-induced allergic asthma by inhibiting AIM2 inflammasome activation. [Abstract]

2026 Mar 25:359:121103. PMID: 41453548
Food Funct

Xanthohumol inhibits tau protein aggregation and protects cells against tau aggregates. [Abstract]

2019 Dec 11;10(12):7865-7874. PMID: 31793596
Eur J Pharmacol

Xanthohumol attenuates collagen synthesis in scleroderma skin fibroblasts by ROS/Nrf2/TGFβ1/Smad3 pathway. [Abstract]

2024 Jan 15:963:176227. PMID: 38072040
Virol Sin

Development of the reverse genetics system for viral hemorrhagic septicemia virus genotype IVa and its application in antiviral compound screening. [Abstract]

2025 Dec 27:S1995-820X(25)00177-4. PMID: 41461367
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
J Nat Med

Xanthohumol attenuates TXNIP-mediated renal tubular injury in vitro and in vivo diabetic models. [Abstract]

2025 Mar;79(2):314-327. PMID: 39752106
Kidney Blood Press Res

Protective effects of Xanthohumol against diabetic nephropathy in a mouse model. [Abstract]

2023;48(1):92-101. PMID: 36592619
Neuroreport

Xanthohumol protect cognitive performance in diabetic model rats by inhibiting protein kinase B/nuclear factor kappa-B pathway. [Abstract]

2021 May 19;32(8):651-658. PMID: 33913932

溶剤 & 溶解度

体外:

DMSO : 83.33 mg/mL (235.13 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.8217 mL

14.1084 mL

28.2167 mL

5 mM

0.5643 mL

2.8217 mL

5.6433 mL

10 mM

0.2822 mL

1.4108 mL

2.8217 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (5.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (5.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

プロトコル

Cell Assay^[3]

In vitro cell proliferation/viability is measured by the MTT test at different time points. 1000 cells/well are plated into 96-multiwell plates in complete medium. Following adhesion, medium is replaced with fresh medium containing the different treatments or vehicle (DMSO in medium). Xanthohumol and EGCG are used in a concentration range from 2.5 to 40 μM, up to 96 hours. 3 hours before each time point, MTT reagent (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) is added to the wells and plates are incubated at 37°C. At the indicated time points, absorbance at 540 nm is then measured by a FLUOstar spectrophotometer.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (278 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Luzak B, et al. Xanthohumol from hop cones (Humulus lupulus L.) prevents ADP-induced platelet reactivity. Arch Physiol Biochem. 2016 Nov 18:1-7 [Content Brief]

[2]. Arnaiz-Cot JJ, et al. Xanthohumol modulates calcium signaling in rat ventricular myocytes: Possible Antiarrhythmic properties. J Pharmacol Exp Ther. 2016 Nov 4. pii: jpet.116.236588 [Content Brief]

[3]. Gallo C, et al. Hop derived flavonoid xanthohumol inhibits endothelial cell functions via AMPK activation. Oncotarget. 2016 Aug 1 [Content Brief]

[4]. Chen PH, et al. The miR-204-3p-targeted IGFBP2 pathway is involved in xanthohumol-induced glioma cell apoptotic death. Neuropharmacology. 2016 Nov;110(Pt A):362-75. [Content Brief]

[5]. Inokoshi J, et al. Expression of two human acyl-CoA:diacylglycerol acyltransferase isozymes in yeast and selectivity of microbial inhibitors toward the isozymes. J Antibiot (Tokyo). 2009;62(1):51-54. [Content Brief]

[6]. Buckwold VE, et al. Antiviral activity of hop constituents against a series of DNA and RNA viruses. Antiviral Res. 2004 Jan;61(1):57-62. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.8217 mL	14.1084 mL	28.2167 mL	70.5418 mL
	5 mM	0.5643 mL	2.8217 mL	5.6433 mL	14.1084 mL
	10 mM	0.2822 mL	1.4108 mL	2.8217 mL	7.0542 mL
	15 mM	0.1881 mL	0.9406 mL	1.8811 mL	4.7028 mL
	20 mM	0.1411 mL	0.7054 mL	1.4108 mL	3.5271 mL
	25 mM	0.1129 mL	0.5643 mL	1.1287 mL	2.8217 mL
	30 mM	0.0941 mL	0.4703 mL	0.9406 mL	2.3514 mL
	40 mM	0.0705 mL	0.3527 mL	0.7054 mL	1.7635 mL
	50 mM	0.0564 mL	0.2822 mL	0.5643 mL	1.4108 mL
	60 mM	0.0470 mL	0.2351 mL	0.4703 mL	1.1757 mL
	80 mM	0.0353 mL	0.1764 mL	0.3527 mL	0.8818 mL
	100 mM	0.0282 mL	0.1411 mL	0.2822 mL	0.7054 mL

Keywords

Xanthohumol

16 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

キサントフモール

Anti-Infection Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Natural Product Library

Anti-Cancer Compound Library

Clinical Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Phenols Library

Pyroptosis Compound Library

Traditional Chinese Medicine Active Compound Library

Flavonoids Library

Anti-Pancreatic Cancer Compound Library

Anti-Obesity Compound Library

Lipid Metabolism Compound Library

Food-Sourced Compound Library

Rare Diseases Drug Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Antiviral Traditional Chinese Medicine Active Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Metabolic Enzyme Compound Library

Mitochondrial Toxicity Compound Library

Cell Death Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Flavor Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Anti-Rheumatic Arthritis Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Mass Spectrometry Natural Product Library

MedChemExpress（MCE）の使用を引用している文献 Xanthohumol

COX アイソフォーム固有の製品をすべて表示

Acyltransferase アイソフォーム固有の製品をすべて表示

HSV アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (16)

溶剤 & 溶解度

プロトコル

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Xanthohumol 関連分類

製品番号: HY-N1067